Event details

Cancer vaccines are a broad type of immunotherapy, aimed at educating a patient’s immune system against the tumor. Suboptimal design of the vaccines and intrinsic barriers, such as a suppressive tumor microenvironment, have limited clinical progress.  However, after several decades we now start seeing signs of efficacy and the potential for new developments and combinatorial approaches sparks hope.

This virtual meeting will bring together experts across disciplines to discuss developments in antigen discovery, preclinical vaccine development and clinical advances in cancer vaccine therapy, and reflect on the ongoing challenges and necessities in the field.

Agenda for the day

Times are displayed in BST

  • Available On Demand

    SESSION I: Antigen discovery and mechanism


    Michal Bassani-Sternberg
    Michal Bassani-Sternberg University Hospital of Lausanne, Switzerland 9:40 - 10:05am Antigen discovery for development of personalized cancer immunotherapies
    Vinod Balachandran
    Vinod Balachandran Memorial Sloan Kettering Cancer Center, USA 10:05 - 10:30am Pancreatic cancer – exceptional survivors to RNA vaccines
    Johanna Olweus
    Johanna Olweus Oslo University Hospital, Norway 10:30 - 10:55am New categories of shared antigens for TCR T cell therapies
  • Available On Demand

    Break


  • Available On Demand

    SESSION II: Vaccine platforms and delivery


    Joshua Brody
    Joshua Brody Mount Sinai, USA 11:15 - 11:40am Therapeutic cancer vaccines: melting large tumors and improving overall survival
    Michelle Brown
    Michelle Brown Moderna, USA 11:40-12:05pm Translational perspectives on individualized neoantigen therapy MRNA-4157 (V940)
    John Schiller
    John Schiller NIH, USA 12:05 - 12:30pm HPV vaccines for the prevention of cervical and other cancers
  • Available On Demand

    Break


  • Available On Demand

    SESSION III: Taking vaccines to the clinic


    Patrick Ott
    Patrick Ott Dana-Farber Cancer Institute, USA 1:30 - 1:55pm - Personalized neoantigen vaccines in patients with melanoma and other solid tumors: milestones and opportunities
    Derin Keskin
    Derin Keskin Dana-Farber Cancer Institute, USA 1:55 - 2:20pm Selection of targeted neoantigens for personalized cancer vaccines
    Elizabeth Jaffee
    Elizabeth Jaffee Johns Hopkins University, USA 2:20 - 2:45pm Converging on a cure for pancreatic cancer

Register

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy. * Required Fields